盐酸环丁基甲基肼 | 1246748-00-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 盐酸环丁基甲基肼
• 英文名称: (Cyclobutylmethyl)hydrazine dihydrochloride
• 英文别名: cyclobutylmethylhydrazine;dihydrochloride
• CAS: 1246748-00-4
• 化学式: C5H14Cl2N2
• 分子量: 173.08
• InChiKey: DBRNHJWJRZRAMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.09
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  4
• 氢受体数：
  2

文献信息

• Compounds As Cannabinoid Receptor Ligands
  申请人：Wang Xueqing

  公开号：US20100249086A1

  公开（公告）日：2010-09-30

  Cannabinoid receptor ligands of formula (I) wherein Ring A and R 1 are as defined in the specification. Compositions including such compounds, and methods of treating conditions and disorders using such compounds and compositions are also described.

  大麻素受体配体的化学式（I），其中环A和R1如规范中所定义。还描述了包括这些化合物的组合物，以及使用这些化合物和组合物治疗疾病和疾病的方法。
• PYRAZOLE COMPOUND
  申请人：Sasaki Izumi

  公开号：US20130116296A1

  公开（公告）日：2013-05-09

  The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT 2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT 2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 3 and R 4 are independently hydrogen or C 1-6 alkyl etc.; R 5 is C 4-7 alkyl or —(CR 8 R 9 ) r -E; R 6 , R 7 , R 8 and R 9 are independently hydrogen, fluorine or C 1-6 alkyl; A is C 6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C 3-8 cycloalkyl or C 6-10 aryl etc.; L is oxygen, sulfur or —NR 10 —; n is 1, 2 or 3; R 10 is hydrogen or C 1-6 alkyl etc.; and X is hydrogen or halogen etc.

  本发明涉及一种新型的血清素再摄取抑制剂，同时还表现出5-HT2C拮抗作用（抗抑郁和抗焦虑效果），特别是包括化合物（1）的5-HT2C逆作动作：或其药学上可接受的盐，其中R1、R2、R3和R4独立地为氢或C1-6烷基等；R5为C4-7烷基或—(CR8R9)r-E；R6、R7、R8和R9独立地为氢、氟或C1-6烷基；A为C6-10芳基或杂环芳基等；r为1、2、3或4；E为C3-8环烷基或C6-10芳基等；L为氧、硫或—NR10—；n为1、2或3；R10为氢或C1-6烷基等；X为氢或卤素等。
• Pyrazole compound
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US10087146B2

  公开（公告）日：2018-10-02

  The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.

  本发明涉及一种新型血清素再摄取抑制剂，它还具有 5-HT2C 拮抗作用（抗抑郁和抗焦虑作用），特别是 5-HT2C 反激动作用，由化合物（1）组成： 或其药学上可接受的盐 其中R1、R2、R3和R4独立地为氢或C1-6烷基等；R5为C4-7烷基或-(CR8R9)r-E；R6、R7、R8和R9独立地为氢、氟或C1-6烷基； A 是 C6-10 芳基或杂芳基等；r 是 1、2、3 或 4；E 是 C3-8 环烷基或 C6-10 芳基等；L 是氧、硫或-NR10-；n 是 1、2 或 3；R10 是氢或 C1-6 烷基等； X 是氢或卤素等。
• COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Abbott Laboratories

  公开号：EP2411371A1

  公开（公告）日：2012-02-01
• US8236822B2
  申请人：——

  公开号：US8236822B2

  公开（公告）日：2012-08-07